1 Erythrovirus B19 (B19V) in patients with acute febrile illness

2 suspected of arboviruses in Mato Grosso do Sul, Brazil

- Gislene Garcia C. Lichs^{1,5}, Zoraida del Carmen Fernandez Grillo², Valdinete Alves do 3 Nascimento³, Daniel Maximo Corrêa Alcantara², Everton Ferreira Lemos⁴, Cristiano M. 4 Espínola Carvalho⁶, Luiz Henrique Ferraz Demarchi¹, Crhistinne Carvalho Maymone Gonçalves^{5,7}, Felipe Gomes Naveca^{3,8}, Alexsandra Rodrigues de Mendonça Favacho^{2,5} 5 6 Laboratório Central de Saúde Pública de Mato Grosso do Sul, SES-MS, Campo Grande, Brazil; 1. 7 Fundação Oswaldo Cruz, Fiocruz Mato Grosso do Sul, Campo Grande, Brazil; 2. 8 Núcleo de Vigilância de Vírus Emergentes, Reemergentes ou Negligenciados, Instituto Leônidas e Maria Deane, Fiocruz, 3. 9 Manaus, Amazonas, Brazil; 10 4. Universidade Estadual de Mato Grosso do Sul - UEMS, Campo Grande, Brazil; 11 5. Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil; 12 Universidade Católica Dom Bosco, Campo Grande, Mato Grosso do Sul, Brazil; 6. 13 7. Secretaria de Estado de Saúde de Mato Grosso do Sul, Campo Grande, Brazil; 14 8. Laboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil. 15
- 16 Corresponding author: Gislene Lichs (glichs@hotmail.com)

It is made available under a CC-BY-NC-ND 4.0 International license .

17 Abstract

18 Human Erythrovirus (parvovirus) B19 infection can produce symptoms similar to those 19 produced by Dengue, Chikungunya, and Zika viruses, making clinical diagnosis difficult. The 20 importance of erythrovirus B19 in human pathology has been increased and reported in 21 numerous studies published globally. The B19V infection was investigated by real-time PCR 22 in samples from patients with signs and symptoms related to classic arboviral symptoms. This 23 study was conducted to provide information on the genetic diversity of Human Erythrovirus 24 B19 (B19V) circulating in the state of Mato Grosso do Sul, Midwest region of Brazil, from 25 2017 to 2022. A total of 773 sera samples of patients with negative diagnostic results for 26 Dengue, Chikungunya, and Zika, during the study period were analyzed. Erythrovirus DNA 27 was found in 10.6% (82/773) of patients, among them 10 were pregnant women. Four 28 samples were completely sequenced, and the other five partially, to genotype by phylogenetic 29 reconstruction. All samples belong to worldwide dispersed genotype 1, subgenotype 1a. 30 These results demonstrate the importance of including B19V in differential laboratory 31 diagnosis for epidemiological purposes and appropriate patient management. The diagnosis 32 for B19V should be performed, particularly among pregnant women, immunocompromised

- patients, and individuals with hemolytic diseases, as the infection is more severe in these
- 34 cases.
- 35 Introduction
- 36 Human Erythrovirus B19 (parvovirus B19), of the *Parvoviridae* family, a member of the
- 37 Erythroparvovirus genus, was discovered in England by Yvonne Cossart et al in 1975 [1] in
- 38 serum samples from blood donors who performed serological testing for hepatitis B virus.
- 39 This sample was coded as "number 19 in panel B", and later the virus was called B19 [1].
- 40 After its discovery, the B19V infection was associated with an asymptomatic or benign acute
- 41 pediatric infection known as erythema infectiosum and other clinical manifestations such as
- 42 transient aplastic crisis, and arthropathies [2].
- 43 The transmission of B19V is through the respiratory droplets. However, the virus can also be
- transmitted parenterally, especially by haemoderivative applications [3]. The Erythrovirus
- 45 B19 has a tropism for human erythroid progenitor cells and it is involved in suppressing
- 46 blood cell formation during infection [4]. In 2002, the virus was classified into three
- 47 genotypes, defined as genotype 1 B19 classic (represented by the prototype strain Au),
- 48 genotype 2 (prototype K71 and strain A6-similar), and genotype 3 (prototype V9) [5].
- 49 The infection by Human Erythrovirus B19 during pregnancy has been widely studied, and it
- 50 is known to cause a range of complications, including spontaneous abortion [2]. The virus
- 51 acts on the inhibition of red blood cell formation, generating cytotoxic effects that lead to
- 52 variable clinical conditions, such as intrauterine growth retardation, myocarditis, and
- 53 pericardial effusions, which will depend on the patient's hematological and immunological
- 54 status. The age group most affected is children/adolescents under 14 years old [6]. However,
- 55 many infections are asymptomatic and are not correctly diagnosed.
- 56 In Brazil, the B19V and some arboviruses (Dengue, Chikungunya, and Zika) co-circulate in
- 57 several regions of the country, making the differential diagnosis difficult, mainly because
- these viruses can cause similar symptoms associated with exanthema and acute febrile
- 59 diseases [7].

It is made available under a CC-BY-NC-ND 4.0 International license .

- 60 The disease caused by B19V was not classified as national or state compulsory notification,
- 61 in Brazil. The infection was detected in surveillance of exanthematous diseases, as a
- 62 differential diagnosis in suspected cases of measles or rubella, according to the characteristics
- 63 of symptoms [8]. In 2020, in a meeting between the State Secretary of Health of Mato Grosso
- do Sul (SES) and the Central Laboratory of Public Health (LACEN) it was agreed that
- 65 suspected cases of Erythema Infectiosum (B19V) should be notified, but it was only from
- 66 2021 that some cases were included in the Notification Diseases Information System
- 67 (SINAN). The detection of IgM antibodies against parvovirus B19 is carried out at the
- 68 LACEN following national guidelines and protocols provided by the Ministry of Health.
- 69 Diagnosis for B19V, using real-time PCR, should be performed particularly among pregnant
- 70 women, immunocompromised patients, and individuals with hemolytic diseases since the
- 71 infection is more serious in these cases. The implementation in the laboratory routine can
- 72 clarify whether erythrovirus B19 may be one of the etiological agents of exanthematous
- 73 diseases, as well as determine the frequency of their infection in patients.
- 74 The current study aims to evaluate the presence of Human Erythrovirus B19 in samples from
- 75 patients with negative diagnostic results for Dengue, Chikungunya, and Zika collected in
- several municipalities in the state of Mato Grosso do Sul, Brazil, from 2017 to 2022, and
- 77 provide information of molecular characterization and genetic variability of circulating
- 78 strains of Human Erythrovirus B19 in the state.
- 79
- 80 Materials and Methods

81 Study design and sampling

- 82 Biological samples were selected from the Biobank of the Central Laboratory of Public
- 83 Health of Mato Grosso do Sul state (LACEN/MS), based on the following criteria: (i) serum,
- 84 urine, and cerebrospinal fluid samples collected between January 2017 and October 2022; (ii)
- 85 with clinical suspicion of chikungunya, dengue or zika disease but with negative test results

86 ("not detectable" by the RT-qPCR and "non-reactive" when using the NS1 and enzyme-

- 87 linked immunosorbent assay (ELISA) for these arboviruses; (iii) reported onset of symptoms
- 88 within 5 days for the NS1 test; and (iv) availability at the time of sample selection, since a
- 89 substantial number of samples were discarded during the laboratory routine due to a lack of
- 90 storage capacity, a condition exacerbated by the SARS-CoV-2 pandemic; v) samples with a
- 91 volume equal or more than 200 microliters.
- 92 Socio-demographic and clinical data of each sample were obtained from the medical request
- 93 forms to assess associations with Erythrovirus B19 infection, including, gender, age, city of
- 94 residence, reported symptoms, pregnancy, and confirmation of death. In addition, the records
- 95 of positive cases of CHIKV, DENV, and ZIKV during the routine diagnosis of LACEN/MS
- 96 were compared with the qPCR results obtained for B19V in the present study.

97 Ethical Approval

- 98 This study was conducted with the authorization of the Human Research Ethical Committee
- 99 of the Dom Bosco Catholic University of Mato Grosso do Sul, Brazil
- 100 (CAAE:54019821.2.0000.5162).

It is made available under a CC-BY-NC-ND 4.0 International license .

101 Virus detection

- 102 The nucleic acids of each sample were extracted using the QIAsymphony
- 103 DSPVirus/Pathogen Mini Kit (QIAGEN), according to the manufacturer's protocol. The
- 104 extracted DNA was tested for B19V using the protocol developed by Naveca et al. (data not
- 105 yet published) from the Leônidas and Maria Deane Institute (ILMD), Fiocruz Amazônia.
- 106 Primers and probes are presented in Table S1. Real-time PCR (qPCR) was performed using
- 107 the KAPA PROBE FAST qPCR Master Mix (2X) (Roche), following the calculations shown
- 108 in Table S2. In all the reactions, the amplification of the human internal control gene (RNase
- 109 P) was used to rule out false negatives, thereby confirming the accuracy of the results. A no-
- 110 template control and positive control for B19V were used to discard possible contamination
- 111 and validate the reaction. The qPCR was performed using the ABI 7500 and QuantStudio[™] 5
- 112 (Applied Biosystems). Following the manufacturer's protocol, it applied an initial
- 113 denaturation at 95°C for 5', with 40 cycles of denaturation at 95°C for 3" and combined
- 114 annealing/extension/data acquisition at 60°C for 30". The threshold for the quantification
- 115 cycle (Cq) was calculated automatically with default settings using equipment software. The
- 116 results were considered "positive" for B19V when the Cq value was \leq 37.

117 Sequencing

118 Samples with positive results for B19V were amplified by conventional PCR using three

- 119 pairs of primers (Table S3), covering almost the entire viral genome. Nine samples were
- 120 separated for sequencing (Table 2). They were indicative of the first three years of the study
- 121 and also had a high viral load. PCR reactions were performed using SuperFi II green enzyme
- 122 (Thermo Fisher Scientific), primers at 0.5µM, and 1µL of viral DNA in 10µL of the final
- 123 volume. The recommended cycling parameters were as follows, 98°C of initial denaturation
- 124 for 30", 35 cycles of 10" denaturation at 98°C, 10" annealing at 55°C, 2' extension at 72°C,
- 125 ending with 5' final extension at 72° C.

126 At the end of the reactions, each amplicon was subjected to electrophoresis at 80V for 1 h,

127 visualized on a 1% agarose gel stained with GelRed (Biotium), and the GeneRuler 1 kb DNA

- 128 Ladder (Thermo Fisher Scientific) was used to confirm the expected size of the product.
- 129 Subsequently, the PCR products were precipitated using polyethylene glycol 8000 following
- 130 an adapted protocol. Initially, 20% PEG8000 (Promega) was added at a 1:1 ratio to the tube
- 131 containing the PCR product, followed by incubation at 37°C for 15 min. After incubation,
- 132 centrifugation was performed at $13,000 \times g$ for 15 min. The supernatant was then discarded,
- 133 125 μL of 80% ethanol was added, followed by a new centrifugation step at 12,000 \times g for 2
- 134 min, and the supernatant was discarded. The microtube was then placed in a Mivac DNA
- 135 concentrator (Genevc SP Scientific) for 15 min at 37°C. DNA was then resuspended in
- 136 nuclease-free water and quantified using a microvolume spectrophotometer (Biodrop Duo
- 137 Biochrom). All amplicons from the same sample were pooled together and quantified using
- 138 the Qubit 2.0 and dsDNA HS Assay kit (Thermo Fisher Scientific).
- 139 Four samples were suitable for whole-genome sequencing. Library preparation was
- 140 performed using a Nextera XT DNA Library Prep Kit (Illumina). Enzymatic tagmentation,
- 141 adapter, and index addition, amplification, normalization, and pool libraries were performed
- 142 as described in the manufacturer's manual using 1ng of DNA. All libraries were quantified
- 143 using a Qubit dsDNA HS Assay Kit. Sequencing was performed on MiSeq equipment
- 144 (Illumina) using the Reagent v2 500-cycle sequencing kit. The data generated after
- 145 sequencing were analyzed in Geneious Prime 2022.0.1 software for the assembly of contigs

It is made available under a CC-BY-NC-ND 4.0 International license .

- 146 of each sample, using the genome NC_000883 as the reference and the BBMap v 38.84 tool
- 147 under "default" conditions. The remaining five samples were partially sequenced (ranging
- from 585 to 1281 base pairs of the VP1/VP2 gene) using standard procedures for capillary
- sequencing, as recommended for ABI3130 (ThermoFisher). Trace files were edited for
- 150 quality and primer removal and assembled using the B19V. The nucleotide sequences
- 151 obtained during this study were deposited in the GenBank database (Table 2).

152 **Phylogenetic analysis**

- 153 The consensus B19V sequences obtained in this study and the reference sequences available
- 154 on GenBank [G1a: M13178 (isolated Au); G1b: DQ357064 (isolated Vn147); G2:
- 155 AY064475 (isolated A6); G2 AY044266 (isolated LaLi); G3a: AX003421 (isolated V9) and
- 156 G3b: AY083234 (isolated D91.1)] were aligned using the MAFFT v7.490 tool with
- 157 automatic algorithm selection. Subsequently, the alignment file was subjected to maximum-
- 158 likelihood phylogenetic reconstruction with the FastTree 2.1.11 program using the GTR
- 159 evolutionary model. An approximate likelihood ratio test (aLRT) [9] was used to assess the
- 160 branch supports. The phylogenetic tree had the root placed at the central point, with
- 161 increasing node order, and was edited in the FigTree 1.4.4 program. Tip labels were aligned
- 162 for clarity.

163 Statistical analyses

164 Mixed Generalized Linear Models (GLMMs) with random effects for municipalities and

- 165 binomial distribution were used to understand how PCR test results could be related to (1) the
- age and gender of patients, as well as the year of sampling; and (2) the symptoms recorded in
- 167 patient records. Symptoms were evaluated in a separate model, owing to fewer records.
- 168 Multicollinearity was checked by examining the Pearson correlation coefficient (Pearson's r)
- 169 between each pair of explanatory variables, using the R package 'correlation' [10], and
- 170 computing the variance inflation factor (VIF), with the R package 'performance' [11]. The
- analyses were performed using the 'lme4' package [12] in the R software [13]. Tables and

estimation plots were generated using the 'jtools' package [14]. The models were checked for

173 normality of residuals, normality of random effects, homogeneity of variance, and residual

174 dispersion using the packages 'DHARMa' [15] and 'performance'.

175 In years when sampling was conducted for all months, circular statistics were employed to 176 test seasonal patterns in the number of cases in Mato Grosso do Sul [16-18]. Two approaches 177 were used: (1) a hypothesis test and (2) a model-based approach, both implemented in the R 178 package 'CircMLE' [19]. In the hypothesis test, the null hypothesis is that the data are 179 uniformly distributed throughout the year, versus some form of concentration, be it unimodal, 180 bimodal, or multimodal [18]. The Hermans-Rasson test was used to verify the uniformity of 181 the distributions, as it has high statistical power for grouped multimodal distributions [17]. In 182 the model-based approach, the package calculates the maximum likelihood of 10 models 183 described by [20] and compares them using model selection criteria. Thus, this approach 184 allows the identification of patterns of occurrence. Briefly, the models fall into three main 185 categories: (i) a uniform model (M1) of random orientation; (ii) unimodal models (M2A, 186 M2B, M2C) with a single preferred direction; and (iii) bimodal models (M3, M4, and M5) 187 with two preferred directions. Bimodal models can also be divided into axial (M3A, M3B, 188 M4A, M4B) and non-axial (M5A, M5B) [18-21]. Herein, the models were compared based 189 on Akaike's Information Criterion with small-sample correction (AICc). Additionally, the 190 Akaike weight (w_i) was used, which describes the probability that a particular model is the

It is made available under a CC-BY-NC-ND 4.0 International license .

- 191 best model (approximate), given the experimental data and the collection of models
- 192 considered [21-23]. For each year, it was also calculated the circular standard deviation (sd),
- 193 circular mean (μ), and the length of the mean vector (r) using the R package 'circular' [24].
- 194 The μ represents the mean date of cases, and r represents how the data is clustered around the
- 195 mean (0, perfectly uniformly distributed; and 1, perfectly clustered). All statistical analyses
- 196 were performed using the R software v4.2.1.

197 **RESULTS**

198 Between January 2017 and October 2022, LACEN/MS performed 26,154 tests for at least

- 199 one of the three arboviruses. Some of the samples received for diagnosis of dengue were also
- 200 tested for CHIKV and/or ZIKV, and others were just evaluated for CHIKV and/or ZIKV. Of
- 201 the total samples analyzed, 7,239 were tested for CHIKV, 14,247 for DENV, and 4,668 for
- 202 ZIKV. Of those, 7,162 were negative for CHIKV (98.9%), 7,340 for DENV (51.5%), and
- 203 4,634 for ZIKV (99.3%) (Figure 1). Despite the high number of tests performed, few samples
- were available at the time of sample selection. Therefore, only 773 samples from 62
- 205 municipalities in the state of Mato Grosso do Sul met the previously defined criteria, had
- 206 negative results for dengue, zika, and chikungunya, and were chosen for B19V research
- 207 (Figure 1). Of the total samples analyzed, 82 were positive for B19V (10.6%), from 24
- 208 municipalities (Table 1; Figure 2), surpassing the number of cases registered for
- 209 Chikungunya and Zika during the same period in the state of Mato Grosso do Sul (Figure 3).
- 210 Of the total positive samples, 28 were collected in men and 54 in women (Figure S1), with 10
- 211 pregnant women. The ages of patients ranged from 1 to 70 years, however, B19V detection
- 212 was not significantly associated with gender and age group, although it was significantly
- 213 different between the years of the period evaluated (Figure 4A). The positive results in the
- 214 years 2019, 2021, and 2022 were significantly lower than in 2017 (Table 1; Figure 4A). The
- 215 notification forms of 598 patients contained clinical information, identifying a total of 20
- 216 symptoms. Among B19V-positive patients, fever was the most frequent symptom, followed
- 217 by myalgia, headache, arthralgia, retro-orbital pain, nausea, and rash. (Figure 5). Despite this,
- 218 B19V detection was significantly associated only with retro-orbital pain, leukopenia,
- 219 petechiae, and malaise (Table 1; Figure 4B). The symptom "abdominal discomfort" was not
- 220 included in the model because it was correlated with "diarrhea". The symptoms "gingival
- 221 bleeding", "renal failure", "sore throat" and "thrombocytopenia" were not included because
- they only had 2 cases in the notification forms, causing problems in the estimates.
- 223 The phylogenetic reconstruction showed that all samples sequenced in this study were
- recovered with Genotype 1, subgenotype 1a (RefSeq M13178), with high support (aLRT =
- 225 0.94) (Figure 6). The B19V samples that underwent sequencing originate from different
- 226 municipalities (Corumbá, Campo Grande, Dourados, Deodápolis, Caarapó, Chapadão do Sul,
- 227 and Alcinópolis) in various geographic areas, demonstrating the wide spread of the virus by
- the whole state. Identifiers (CodeID) were created for each sample to ensure the
- 229 confidentiality of the subjects' identities in the study and to prevent recognition by anyone
- 230 outside the research group (Table 2; Figure S2).
- 231 The results of the Hermans-Rasson test demonstrated that the number of cases was seasonal
- for all the years evaluated, 2017 (7.29; p = 0.033), 2018 (13.02; p < 0.001), and 2019 (13.90;
- 233 p < 0.001). For 2017, despite the best model having presented an AICc w_i with more than
- twice the second, the following models can still be considered plausible choices. When
- 235 considering the first two models (M3A and M4A, AICc $w_i = 0.38$ and 0.17; Figure 7; Table

It is made available under a CC-BY-NC-ND 4.0 International license .

236 S4), they together presented an AICc $w_i = 0.55$, which means that there is at least a 55% 237 chance that it is the best approximation that describes the data, given the candidate set of 238 orientations considered. Both models are axial bimodal, suggesting a distribution in two 239 equally sized points in 2017, one in each semester, with the mean date of cases in September 240 (mean date = September 01, 2017; sd = 1.67; r = 0.25). In 2018, no model stood out, and the 241 first two were equally supported, with close AICc w_i values, which, together, presented a 242 value of AICc $w_i = 0.71$ (M5A and M3A, AICc $w_i = 0.38$ and 0.33; Figure 7; Table S5). 243 Although both have a bimodal distribution, one is non-axial (M5A), while the other is 244 (M3A), making it more complicated to determine a pattern for the year 2018. Even so, both 245 models showed a division of distribution between the two semesters, with a greater presence 246 of cases closer to the end of each semester, with the mean date of cases in July (mean date = 247 July 23, 2018; sd = 1.68; r = 0.25). In contrast, the pattern shown in 2019 was unequivocal, 248 with an unimodal distribution (M2A, AICc $w_i = 0.72$; Figure 7; Table S6) concentrated in the

first half, with the average date in March (mean date = March 17, 2019; sd = 1.03; r = 0.59).

250 DISCUSSION

251 A wide variety of viruses can cause rashes and joint pain in children, adolescents, and adults, 252 leading to etiological identification exclusively through clinical examination, which makes it 253 a challenging task. The most common agents of exanthematous disease (ED) include 254 Measles, Rubella, Dengue, Chickenpox, Cytomegalovirus, Epstein Barr, Human HerpesVirus 255 6, Enterovirus, Erythrovirus (Human Parvovirus B19), Chikungunya and Zika [25]. Although 256 these injuries are common in Brazil, there are several difficulties in determining an accurate 257 etiological diagnosis, especially in those regions where there is co-circulation of 258 exanthematous diseases. Therefore, the differential diagnosis of these diseases is extremely 259 important, not only for epidemiological purposes but also for the control and treatment of 260 infections. Even if most of them have a benign course, for certain age groups, pregnant 261 women, and immunocompromised people, some infections represent an important risk, as 262 they can evolve into serious cases, which may require emergency hospitalization, burdening 263 the public health service [6].

264 Molecular diagnosis of B19V infection is not commonly used as a differential diagnosis, and 265 there are no studies dealing with the detection of B19V using the qPCR methodology in the 266 state of Mato Grosso do Sul, Brazil. The continuous lack of specific studies for B19V in the 267 state of Mato Grosso do Sul may be contributing to the high number of cases that are not 268 laboratory-confirmed (Figure 3). This highlights the need to expand laboratory diagnosis so 269 that B19V can be monitored. However, it is important to point out that the use of a sensitive 270 and specific molecular method is of paramount importance for clarifying the laboratory 271 diagnosis of different viral infections. Thus, our study is the first one showing the circulation 272 of B19V in the state of Mato Grosso do Sul, in the Midwest region of Brazil, using the new 273 protocol developed by F.G. Naveca and his team. Also, our study demonstrates the need and 274 feasibility of implementing B19V detection as a differential diagnosis in patients with acute 275 febrile illness or suspicion of arbovirus infection.

Erythrovirus B19 can occur in individuals of all age groups and from different population
groups [26], which is supported by our results (Figure 4A). The B19V infection is usually
characterized as acute and self-limited, but clinical manifestations might vary according to
the immunological and hematological profile of each person [26]. Some studies describe
arthralgia as the most characteristic symptom of B19V infection, especially in adults [27, 28].
Herein, the most common symptoms recorded were, in decreasing order of frequency, fever,

It is made available under a CC-BY-NC-ND 4.0 International license .

282 myalgia, headache, and, only then, arthralgia (Figure 5). Also, the detection of B19V was 283 significantly associated with the symptoms of "retro-orbital pain", "leukopenia", "petechiae" 284 and "malaise" (Figure 4B), thus, diverging from previous studies. However, regardless of the 285 existence of symptoms that might be more associated with B19V infection, there is immense 286 difficulty in distinguishing it from other exanthematous diseases due to the similarity of 287 symptoms. The similarity of the symptoms of erythema infectiosum to other cutaneous 288 exanthematous diseases, together with the wide circulation of arboviruses in Brazil, make the 289 clinical diagnosis a difficult challenge to overcome [6]. In this sense, a study published by 290 [29] showed that about 19% of cases of exanthematous diseases remain without a 291 confirmatory diagnosis; among them, B19V infection is the major cause (33%). Hence, it is 292 essential to carry out a specific laboratory diagnosis for the correct identification of the 293 exanthematous disease agent.

294 In our study, ten pregnant women tested positive for B19V. Infection by B19V during 295 pregnancy is a serious public health problem, as abortion can occur in the first trimester of 296 pregnancy and in the second trimester, the fetus can develop non-immune hydrops fetalis 297 [30]. The infection can result in vertical transmission to the fetus, causing infection of 298 erythroid precursors and intense hemolysis, leading to severe anemia, fetal hydrops, and 299 death. Rapid correction of anemia by transfusion of packed red blood cells in utero largely 300 prevents fetal death [31]. Unfortunately, it was not possible to track the positive pregnant 301 women to verify the outcome of each case, since they were not diagnosed promptly for 302 adequate follow-up during pregnancy. Women of reproductive age have an annual 303 seroconversion rate of 1.5%, and as in the population group of pregnant women the disease 304 tends to be more severe, so the pregnancy must be monitored medically with the detection of 305 B19V [32].

306 The identification of B19V "Genotype 1a" (Figure 6) demonstrates the importance of 307 differential laboratory diagnosis using molecular techniques in patients with fever and 308 characteristic symptoms, to assist the health surveillance system through continuous 309 monitoring to detect all circulating genotypes and the spread of the virus in the population. 310 There are three recognized genotypes of B19V (1, 2, and 3), segregated into subtypes 1a, 1b, 311 2, 3a, and 3b [4, 33-35]. All three genotypes have been reported in both symptomatic and 312 asymptomatic persons, and no association has been established between genotype and clinical 313 manifestations [36-41]. Genotype 1 is the most prevalent in the world. In Brazil, the three 314 genotypes have already been detected, but there is also a predominance of Genotype 1[42, 315 43]. The first complete genome of B19V genotype 1 a was from a serum sample suspected of 316 dengue infection, from a fatal case of a 12-year-old boy in Rio de Janeiro, Brazil [35]. The 317 viral genome of erythrovirus B19 is highly conserved, with 98-99% similarity between 318 isolates [44, 45], which means that a few sequenced samples are enough to know the 319 circulating genotype.

320 An important characteristic of B19V infection in Brazil is its cyclic pattern of occurrence 321 every 3 to 5 years, observing years with high infection rates followed by periods with low 322 circulation, as occurred in 1988-1989, 1995-1996, 1999- 2000, 2004-2005, 2009-2010, 2013-323 2014 [46, 47]. Our results corroborate these previous studies, suggesting that B19V has a 324 cyclical pattern of occurrence in Mato Grosso do Sul (Figure 7). There was a greater number 325 of cases in 2017 and 2018, having decreased in 2019, rising again in 2020, and decreasing 326 again in 2021 and 2022, with a positivity percentage of 20.7%, 13.75%, 8.8%, 18.3%, 2.3% 327 and 3.4% respectively (Table 1; Figures 3 and 4A). However, further studies are needed over 328 a longer period, since the cycle can last from 4 to 5 years [46]. Additionally, as three years of

It is made available under a CC-BY-NC-ND 4.0 International license .

329 the study overlapped with the COVID-19 pandemic, this may also have influenced the

330 dynamics of circulation and transmission of B19V.

331 CONCLUSION

332 Timely information represents an essential tool for epidemiological surveillance, as it triggers 333 the "information-decision-action" process, a triad that summarizes the dynamics of its 334 activities, which, as is known, must be initiated from the information of an indication or 335 suspected case of any disease or injury. Although not a new concern, our study demonstrates 336 the importance of the differential diagnosis of B19V in the population, with main attention to 337 pregnant women. As an example, clinical and epidemiological studies carried out in the 338 North region, in 1993, already showed that B19V was becoming a public health problem on 339 the rise at that time [48]. Our study population did not have a laboratory-confirmed diagnosis 340 and, therefore, surveillance did not carry out control actions. This evidences the need for 341 investment in the implementation of methodologies that maintain a high sensitivity of viral 342 detection in areas at risk of emergence of emerging and reemerging pathogens. By identifying 343 the agent that is affecting the population, medical conduct and epidemiological surveillance 344 actions will be better directed. Further, continuous monitoring is needed to detect all known 345 genotypes and the emergence of new genotypes for the control of cases.

346 TABLES

Year	Samples	Positives (%)	Municipalities sampled	Municipalities with positive cases (%)
2017	82	17 (20.7)	28	10 (35.7)
2018	160	22 (13.8)	27	10 (37.0)
2019	285	25 (8.8)	39	11 (28.2)
2020	71	13 (18.3)	22	6 (27.3)
2021	86	2 (2.3)	15	1 (6.7)
2022	89	3 (3.4)	22	3 (13.6)
Total	773	82 (10.6)	62	24 (38.7)

Table 1: Population and municipalities studied by year and positive cases for B19V.

349	Table 2: Characteristics of samples sequenced to identify the circulating B19V genotype. All municipalities are in the state of Mato Grosso do Sul,
350	Brazil. The GenBank access numbers are shown for each sample.

Code ID	Gender Municipa		Collection date	Pregnancy	Accession number	
MS-B19-17-201-532	Woman	Dourados	03/2017	Yes	OR542579	
MS-B19-17-32-174	Woman	Chapadão do Sul	05/2017	No	OR542583	
MS-B19-17-25-839	Woman	Corumbá	05/2017	Yes	OR542582	
MS-B19-17-201-1400	Woman	Dourados	07/2017	Yes	OR578525	
MS-B19-17-18-408	Woman	Caarapó	08/2017	No	OR542580	
MS-B19-17-31-100	Woman	Eldorado	10/2017	No	OR578526	
MS-B19-17-31-148	Man	Eldorado	11/2017	-	OR578523	
MS-B19-18-102-7397	Man	Campo Grande	07/2018	-	OR578524	
MS-B19-19-04-3 Woman Alcinópolis		Alcinópolis	01/2019	No	OR542581	

351 -,

not

applicable.

It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .

352 FIGURES




Figure 1. Flowchart of the experimental design of the present study.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 2. Positive cases of B19V, according to municipalities in the state of Mato Grosso do

³⁵⁸ Sul, during the period from 2017 to 2022.

It is made available under a CC-BY-NC-ND 4.0 International license .






Figure 3. Samples of arboviruses surveyed at LACEN/MS and their results compared to
 B19V, from 2017 to 2022. The bar graph shows the proportion of molecular test results for
 all arboviruses examined in LACEN/MS. The lines indicate the percentage of positive results
 for each virus.





It is made available under a CC-BY-NC-ND 4.0 International license .

- **Figure 4.** Estimates of mixed generalized linear models. (A) Estimates of patient
- 367 characteristics and period. (B) Estimates of symptoms. Filled dots indicate significant
- 368 variables (p < 0.05); bars represent the 95% confidence interval; β , estimate; numbers in
- 369 parentheses indicate the estimated 95% confidence intervals; p, p-value.



372 Figure 5. Frequency of symptoms by age group of the studied population.





- 376 obtained from GenBank are identified by their accession number. The numbers above
- 377 branches indicate the approximate likelihood ratio test (aLRT).






Figure 7. Circular histograms of several B19 cases per month for the years 2017, 2018, and 2019. In the larger histogram, the numbers indicate the number of cases in the respective month, and the mean vector (arrow) is the length and direction of the mean date of cases. The smaller histograms represent the best models found, with the average vector (arrow), the

density (dashed line), and the average direction (dashed arrows).

385

386 Data Availability

The data that support the findings of this study will be made available in the supplementaryof this article.

389 Conflicts of Interest

390 The authors declare no conflicts of interest.

391 Authors' Contributions

- 392 Conceptualization: G.G.C.L, Z.C.F.G, F.G.N, and A.R.M.F; methodology: G.G.C.L, F.G.N,
- 393 Z.C.F.G, V.A.N, E.F.L, D.M.C.A, and A.R.M.F; investigation: G.G.C.L, Z.C.F.G, V.A.N,
- 394 D.M.C.A, F.G.N and A.R.M.F; resources: A.R.M.F, Z.C.F.G, C.M.E.C, L.H.F.D and
- 395 C.C.M.G; data curation: G.G.C.L, V.A.N, E.F.L, F.G.N, D.M.C.A and A.R.M.F; writing -
- 396 preparation of the original draft: G.G.C.L, A.R.M.F, Z.C.F.G, E.F.L, D.M.C.A, V.A.N, and
- 397 F.G.N; writing proofreading and editing: G.G.C.L, Z.C.F.G, A.R.M.F, D.M.C.A, V.A.N,
- 398 E.F.L, C.M.E.C, L.H.F.D, C.C.M.G and F.G.N; formal analysis: G.G.C.L, Z.C.F.G,
- 399 A.R.M.F, D.M.C.A, V.A.N and F.G.N; statistical analysis: G.G.C.L and D.M.C.A;
- 400 supervision: A.R.M.F and Z.C.F.G; financing acquisition: A.R.M.F, Z.C.F.G, C.M.E.C,

It is made available under a CC-BY-NC-ND 4.0 International license .

- 401 L.H.F.D and C.C.M.G. All authors read and agreed with the published version of the
- 402 manuscript.

403 Funding Statement

- 404 This work was supported by the Foundation Oswaldo Cruz: Fiocruz Mato Grosso do Sul,
- 405 Fiocruz Amazônia and Fiocruz Rio de Janeiro, the Central Public Health Laboratory/Mato
- 406 Grosso do Sul (LACEN) and the Mato Grosso do Sul State Health Secretaria (SES) and
- 407 Evandro Chagas institute.

408 Acknowledgments

- 409 The authors would like to thank the Central Public Health Laboratory/Mato Grosso do Sul
- 410 (LACEN) and the Mato Grosso do Sul State Health Secretaria (SES) for their support in
- 411 carrying out the analyses. The authors also thank FIOCRUZ/MS, FIOCRUZ/AM,
- 412 FIOCRUZ/RJ, and Evandro Chagas institute for their support and supply of control samples.

413 Supplementary Materials

- 414 Supplementary 1. Table S1. Primers and probes were used in the study for B19V detection
- 415 (NAVECA et al., unpublished data).
- 416 Supplementary 2. Table S2. Components and volumes used to prepare the reactions for B19V
- 417 detection (NAVECA et al., unpublished data).
- Supplementary 3. Table S3. Primers and probes are used for amplification of the entiregenome of B19V.
- Supplementary 4. Table S4. Results for 2017 data, with comparison for all 10 orientationmodels implemented in the R package 'CircMLE'.
- Supplementary 5. Table S5. Results for 2018 data, with comparison for all 10 orientation
 models implemented in the R package 'CircMLE'.
- Supplementary 6. Table S6. Results for 2019 data, with comparison for all 10 orientationmodels implemented in the R package 'CircMLE'.
- 426 Supplementary 7. Figure S1. Age group and gender of sampled patients. n, number of427 patients sampled by age group.
- 428 Supplementary 8. Figure S2. The B19V samples that underwent sequencing originate from
- different municipalities in different geographic areas, demonstrating the wide disseminationof the virus throughout the state.

431 **ORCID**

- 432 Gislene Lichs ^[] <u>https://orcid.org/0000-0002-0359-4444</u>
- 433 Zoraida del Carmen Fernandez https://orcid.org/0000-0003-2393-946X
- 434 Valdinete A Nascimento <u>https://orcid.org/0000-0002-7786-4718</u>
- 435 Daniel Maximo Corrêa Alcantara https://orcid.org/0000-0002-8333-377X
- 436 Everton Lemos <u>https://orcid.org/0000-0001-6652-9191</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

- 437 Crhistinne Carvalho Maymone Gonçalves <u>https://orcid.org/0000-0001-6953-4965</u>
- 438 Cristiano M. Espínola Carvalho <u>https://orcid.org/0000-0002-3867-9528</u>
- 439 Luiz H Demarchi https://orcid.org/0000-0001-8693-7897
- 440 Felipe G Naveca https://orcid.org/0000-0002-2888-1060
- 441 Alexsandra R.M. Favacho https://orcid.org/0000-0002-4950-2357
- 442
- 443 References
- 444
- 445 1. YE, C., et al., *Parvovirus-like particles in human sera*. Lancet (London, England), 1975. 1(7898).
- 447 2. Moore, T.L.M., *Parvovirus-associated arthritis: Current Opinion in Rheumatology*.
 448 2023.
- 449 3. Cotmore, S.F., et al., *The family Parvoviridae*. Archives of Virology, 2013. 159(5): p. 1239-1247.
- 451 4. A, S., et al., *Genetic diversity within human erythroviruses: identification of three* 452 *genotypes.* Journal of Virology, 2002. 76(18).
- 453 5. A, d.S.C., et al., *Detection of the human parvovirus B19 in a blood donor plasma in*454 *Rio de Janeiro*. Memorias do Instituto Oswaldo Cruz, 2023. 84(2): p. 279-280.
- 455 6. Cnc Garcia, R. and L.A. Leon, *Human parvovirus B19: a review of clinical and* 456 *epidemiological aspects in Brazil.* Future Microbiol, 2021. 16(1): p. 37-50.
- 4577.Alves, A. Beyond arboviruses: A multicenter study to evaluate the differential458diagnosis of rash diseases and acute febrile illness cases in Rio de Janeiro, Brazil /459PLOSONE.2023;Availablefrom:460https://iournels.plos.org/plosope/orticle?id=10.1271/iournel.pone.0271758
- 460 <u>https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271758</u>.
- 461 8. RC, C., et al., *Human parvovirus B19 infections among exanthematic diseases*462 *notified as measles.* Revista da Sociedade Brasileira de Medicina Tropical, 1997.
 463 30(1).
- 464 9. Anisimova, M., et al., *Approximate Likelihood-Ratio Test for Branches: A Fast,*465 *Accurate, and Powerful Alternative.* Systematic Biology, 2006. 55(4): p. 539-552.
- 466 10. Makowski, CRAN Package jtools. 2023.
- 46711.Lüdecke, D., et al., performance: An R Package for Assessment, Comparison and468Testing of Statistical Models. Journal of Open Source Software, 2021. 6(60): p. 3139.
- 469 12. Bates, D., et al., *Fitting Linear Mixed-Effects Models using lme4*. 2014.
- 470 13. Team, R.C. *R: The R Project for Statistical Computing*. 2022; Available from: https://www.r-project.org/.
- 472 14. Long, CRAN Package jtools. 2023.
- 473 15. Harting, CRAN Package DHARMa. 2023.
- 474 16. Almeida, A., C. Codeço, and P.M. Luz, *Seasonal dynamics of influenza in Brazil: the*475 *latitude effect.* BMC Infectious Diseases, 2018. 18(1): p. 1-9.
- 476 17. L, L., R. GD, and M. EP, *The Hermans-Rasson test as a powerful alternative to the*477 *Rayleigh test for circular statistics in biology*. BMC Ecology, 2019. 19(1).
- 478 18. Landler, L., et al., Model selection versus traditional hypothesis testing in circular statistics: a simulation study. Biology Open, 2020. 9(6).
- 480 19. RR, F. and J. S, *Bringing the analysis of animal orientation data full circle: model-*481 *based approaches with maximum likelihood.* The Journal of Experimental Biology,
 482 2017. 220(Pt 21).
- 483 20. Schnute, J., Statistical analysis of animal orientation data. 1992.
- 484 21. Ojeda, V., et al., *Latitude does not influence cavity entrance orientation of South*485 *American avian excavators*. Ornithology, 2022. 138(1).
- 486 22. Burnham, K.P., D.R. Anderson, and K.P. Huyvaert, AIC model selection and

487		multimodel inference in behavioral ecology: some background, observations, and
488		comparisons. Behavioral Ecology and Sociobiology, 2010. 65(1): p. 23-35.
489	23.	S, P., A primer on model selection using the Akaike Information Criterion. Infectious
490		Disease Modelling, 2020. 5.
491	24.	Agostineli, C. R-Forge: Circular Statistics: Project Home. 2023; Available from:
492		https://r-forge.r-project.org/projects/circular/.
493	25.	E, M., et al., Laboratory assessment and diagnosis of congenital viral infections:
494		Rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus
495		(HSV), parvovirus B19 and human immunodeficiency virus (HIV). Reproductive
496		toxicology (Elmsford, N.Y.), 2006. 21(4).
497	26.	Qiu, J., M. Söderlund-Venermo, and N.S. Young, <i>Human Parvoviruses</i> . 2016.
498	27.	Suzuki, M., et al., Parvovirus B19 Infection: A Vasculitis Masquerade in an Elderly
499	27.	Patient. American Journal of Case Reports, 2023. 24.
500	28.	Young, N.S. and K.E. Brown, <i>Parvovirus B19</i> . <u>https://doi.org/10.1056/NEJMra</u>
500	20.	<u>030840</u> , 2004.
502	29.	T, V.A., et al., [Incidence and clinical characteristics of maculopapular exanthemas
503		of viral etiology]. Atencion primaria, 2003. 32(9).
504	30.	Bouraddane, M., K. Warda, and S. Zouhair, Parvovirus B19, and Pregnant Women: A
505		Bibliographic Review. Open Journal of Obstetrics and Gynecology, 2021. 11(11): p.
506		1543.
507	31.	SN, S., et al., Molecular and phylogenetic analyses of human Parvovirus B19 isolated
508		from Brazilian patients with sickle cell disease and β -thalassemia major and healthy
509		blood donors. Journal of Medical Virology, 2012. 84(10).
510	32.	WC, K. and A. SP, Human parvovirus B19 infections in women of childbearing age
511		and within families. The Pediatric Infectious Disease Journal, 2023. 8(2): p. 83-87.
512	33.	Toan, N.L., et al., Phylogenetic analysis of human parvovirus B19, indicating two
513		subgroups of genotype 1 in Vietnamese patients. 2006.
514	34.	Parsyan, A., et al., Identification and genetic diversity of two human parvovirus B19
515		genotype 3 subtypes. 2007.
516	35.	Conteville, L.C., et al., Parvovirus B19 1A complete genome from a fatal case in
517		Brazil. Memórias do Instituto Oswaldo Cruz, 2023. 110: p. 820-821.
518	36.	Sanabani, S., et al., Sequence Variability of Human Erythroviruses Present in Bone
519		Marrow of Brazilian Patients with Various Parvovirus B19-Related Hematological
520		Symptoms. 2006.
521	37.	MW, Md.B., et al., Global co-existence of two evolutionary lineages of parvovirus
522		B19 1a, different in genome-wide synonymous positions. PloS One, 2012. 7(8).
523	38.	Rahiala, J., et al., Human parvoviruses B19, PARV4 and bocavirus in pediatric
524		patients with allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2013.
525		48(10): p. 1308-1312.
526	39.	Oliveira, M.I.d., et al., Genotype 1 of human parvovirus B19 in clinical cases. Revista
527		da Associação Médica Brasileira, 2017. 63: p. 224-228.
528	40.	Seetha, D., et al., Molecular-genetic characterization of human parvovirus B19
529		prevalent in Kerala State, India. Virology Journal, 2021. 18(1): p. 1-8.
530	41.	M, H., et al., Parvovirus B19 infection in pediatric allogeneic hematopoietic cell
531		transplantation - Single-center experience and review. Transplant infectious disease:
532		an official journal of the Transplantation Society, 2023. 25(2).
533	42.	RB, F., et al., Molecular characterization of human erythrovirus B19 strains obtained
534		from patients with several clinical presentations in the Amazon region of Brazil.
535		Journal of Clinical Virology: the official publication of the Pan American Society for
536		Clinical Virology, 2008. 43(1).

It is made available under a CC-BY-NC-ND 4.0 International license .

537 538 539	43.	RC, C.G., et al., <i>Molecular diversity of human parvovirus B19 during two outbreaks of erythema infectiosum in Brazil.</i> The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases, 2017. 21(1).
540	44.	Hicks, K.E., et al., Sequence analysis of a parvovirus B19 isolate and baculovirus
541		expression of the non-structural protein. Archives of Virology, 2023. 141(7): p. 1319-
542		1327.
543	45.	Cubel, R.C.N., et al., Human parvovirus B19 infections among exanthematic diseases
544		notified as measles. Revista da Sociedade Brasileira de Medicina Tropical, 1997. 30:
545		p. 15-20.
546	46.	Oliveira, M.I.d., et al., Genotype 1 of human parvovirus B19 in clinical cases. Revista
547		da Associação Médica Brasileira, 2023. 63: p. 224-228.
548	47.	Garcia, R.d.C. and L.A. Leon, Human parvovirus B19: a review of clinical and
549		epidemiological aspects in Brazil. https://doi.org/10.2217/fmb-2020-0123, 2021.
550	48.	Freitas, R.B.d., et al., Parvovirus B19 antibodies in sera of patients with unexplained

exanthemata from Belém, Pará, Brazil. 1993.

It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Material

Erythrovirus B19 (B19V) in patients with acute febrile illness suspected of arboviruses in Mato Grosso do Sul, Brazil

Table S1. Primers and probes used in the study for B19V detection (NAVECA et al., unpublished data).

Oligonucleotides	Sequence
B19_FNF	5' ACAAGCCTGGGCAAGTTAGC 3'
B19_FNR	5' CATTRCCAGGCCCAACAT 3'
B19_FN_P	5' (FAM) TACAACTACCCGGTACTAAC 3'

Table S2. Components and volumes used to prepare the reactions for B19V detection(NAVECA et al., unpublished data).

Component	10 µl reaction
Nuclease-free water	1.4 μL
2X PCR Master Mix Kapa Probe	5 µL
Primer mix (5 µM)	0.6 µL
Probe (10µM) FAM	0.1 µL
Rox Dye	0.4 µL
Template DNA	2.5 μL

It is made available under a CC-BY-NC-ND 4.0 International license .

Name	Sequence 5'- 3'	Length (bp)	
B19V_350FNF (forward)	CGGCATCTGATTTGGTGTCTTC	2037	
B19V_2387FNR (reverse)	CACACATAATCAACCCCAACTAACA	2037	
B19V_1605FNF (forward)	AAGTACAGGAAAAACAAACTTGGCAA	2258	
B19V_3862FNR (reverse)	GTAAGCATATTGAGGGGGAAAGTATAC	2230	
B19V_3298FNF (forward)	CCCAAGCATGACTTCAGTTAATTCT	1679	
B19V_4976FNR (reverse)	GGAGTGTTTACAATGGGTGCAC	1077	

Table S3. Primers and probes used for amplification of the entire genome of B19V.

Table S4. Results for 2017 data, with comparison for all 10 orientation models implemented in the R package 'CircMLE'. The models are described by five parameters: the mean direction (φ 1, in degrees) and concentration parameter (*k*1) for the first mode, the mean direction (φ 2, in degrees) and concentration parameter (*k*2) for the second mode, and the proportional size of the first distribution (λ ; the second distribution is thus fixed at size $1-\lambda$). They were classified based on Akaike's Information Criterion with small-sample correction (AICc). Δ AICc, delta AICc; AICc *w_i*, model weights; ER, evidence ratio.

Modelo	φ1	<i>k</i> 1	λ	ф2	k2	AICc AAIC c		AICc w _i	ER
M3A	4.40	3.18	0.50	7.54	3.18	59.11	0.00	0.38	-
M4A	4.39	3.20	0.65	7.53	3.20	60.68	1.58	0.17	2.20
M2C	4.66	49.99	0.25	-	0.00	61.27	2.17	0.13	2.96
M2B	4.50	5.80	0.50	-	0.00	61.60	2.50	0.11	3.49
M3B	4.45	4.05	0.50	7.59	1.64	61.81	2.70	0.10	3.86
M1	-	0.00	1.00	-	0.00	62.49	3.38	0.07	5.43
M4B	1.25	3.02	0.36	4.39	3.29	64.16	5.06	0.03	12.53
M2A	4.25	0.51	1.00	-	0.00	65.23	6.13	0.02	21.40
M5B	4.36	3.31	0.64	1.31	3.02	68.20	9.10	0.00	94.38
M5A	3.45	5.00	0.41	2.66	5.00	200000011.33	1999999952.23	0.00	-

Table S5. Results for 2018 data, with comparison for all 10 orientation models implemented in the R package 'CircMLE'. The models are described by five parameters: the mean direction (φ 1, in degrees) and concentration parameter (*k*1) for the first mode, the mean direction (φ 2, in degrees) and concentration parameter (*k*2) for the second mode, and the proportional size of the first distribution (λ ; the second distribution is thus fixed at size $1-\lambda$). They were classified based on Akaike's Information Criterion with small-sample correction (AICc). Δ AICc, delta AICc; AICc *w_i*, model weights; ER, evidence ratio.

Modelo	ф1	<i>k</i> 1	λ	ф2	k2	AICc	ΔAICc	AICc w _i	ER
M5A	5.08	4.62	0.47	2.49	4.62	71.17	0.00	0.38	-
M3A	5.37	3.63	0.50	8.51	3.63	71.44	0.27	0.33	1.15
M4A	2.23	3.64	0.54	5.37	3.64	74.04	2.87	0.09	4.20
M3B	2.26	4.48	0.50	5.40	2.84	74.05	2.88	0.09	4.22
M5B	2.49	4.49	0.54	5.09	4.82	74.56	3.39	0.07	5.45
M4B	2.25	4.10	0.53	5.39	3.15	77.03	5.86	0.02	18.73
M2C	2.12	30.86	0.25	-	0.00	79.63	8.46	0.01	68.53
M2B	2.26	16.46	0.50	-	0.00	80.36	9.19	0.00	98.94
M1	-	0.00	1.00	-	0.00	80.87	9.70	0.00	127.51
M2A	3.55	0.51	1.00	-	0.00	82.80	11.63	0.00	335.68

Table S6. Results for 2019 data, with comparison for all 10 orientation models implemented in the R package 'CircMLE'. The models are described by five parameters: the mean direction (φ 1, in degrees) and concentration parameter (*k*1) for the first mode, the mean direction (φ 2, in degrees) and concentration parameter (*k*2) for the second mode, and the proportional size of the first distribution (λ ; the second distribution is thus fixed at size $1-\lambda$). They were classified based on Akaike's Information Criterion with small-sample correction (AICc). Δ AICc, delta AICc; AICc *w_i*, model weights; ER, evidence ratio.

Modelo	φ1	<i>k</i> 1	λ	ф2	k2	AICc	ΔAICe	AICc w _i	ER
M2A	1.31	1.46	1.00	-	0.00	77.34	0.00	0.72	-
M5A	0.33	2.58	0.37	1.82	2.58	81.43	4.09	0.09	7.73
M2C	1.33	2.15	0.75	-	0.00	81.65	4.32	0.08	8.66
M2B	1.39	2.36	0.50	-	0.00	82.11	4.78	0.07	10.89
M3B	4.62	0.00	0.50	7.76	2.24	84.84	7.51	0.02	42.64
M4B	4.40	0.00	0.27	7.54	2.30	85.00	7.67	0.02	46.20
M5B	6.28	2.53	0.49	1.71	3.82	88.08	10.74	0.00	215.33
M1	-	0.00	1.00	-	0.00	91.89	14.56	0.00	1450.15
M3A	1.52	0.98	0.50	4.66	0.98	95.82	18.48	0.00	10315.06
M4A	5.56	0.81	0.25	8.70	0.81	96.28	18.95	0.00	13008.91

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure S1. Age group and gender of sampled patients. n, number of patients sampled by age group.

Figure S2. The B19V samples that underwent sequencing originate from different municipalities in different geographic areas, demonstrating the wide dissemination of the virus throughout the state.

